{
    "nct_id": "NCT03696771",
    "official_title": "A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies",
    "inclusion_criteria": "* Patient must have known histologically or cytologically confirmed and documented HER2-positive solid tumor excluding patients with breast cancer\n* Advanced/metastatic cancer with measurable disease as determined by RECIST v.1.1 who have progressed or are intolerant to all approved therapies known to confer clinical benefit.\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤2.\n* Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy prior to therapy, and during therapy on this study.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of severe hypersensitivity to any ingredient of study drug, trastuzumab or other monoclonal antibody.\n* Patients previously treated with TLR 7/8 agonist.\n* Impaired cardiac function or history of clinically significant cardiac disease\n* Active, known or suspected autoimmune disease.\n* Human Immunodeficiency virus (HIV) infection\n* History of or current interstitial lung disease or pneumonitis Grade 2 or greater.\n* Discontinued prior checkpoint inhibitor due to a checkpoint inhibitor related toxicity.\n* Currently receiving medications known to cause Torsades de Pointe that cannot be discontinued 7 days prior to starting treatment\n\nOther protocol defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}